ABSTRACT
Magnapen is a combination of two well-proven semi-snythetic penicillins which together offer the theoretical advantages of a broad spectrum of activity, good bioavailability and a low incidence of side-effects. It is of particular value in treating infections in the elderly. In this study the theory is borne out in practice in a population presenting special problems for which this combination seems particularly appropriate. Ninety-six patients have been treated with a course of Magnapen syrup. Of the total entered into the study, 73% of patients were clinically cured following therapy, with a further 19% improved. Clinical failure occurred in 8% of patients. Fifty-two patients were bacteriologically assessable, forty-seven of whom (90%) had infecting organisms cleared by therapy. Side-effects occurred in four patients (4%), one of whom had to discontinue therapy.
Subject(s)
Ampicillin/therapeutic use , Bacterial Infections/drug therapy , Cloxacillin/analogs & derivatives , Floxacillin/therapeutic use , Administration, Oral , Aged , Ampicillin/administration & dosage , Ampicillin/metabolism , Biological Availability , Drug Combinations , Female , Floxacillin/administration & dosage , Floxacillin/metabolism , Humans , Male , Middle AgedABSTRACT
A case of the syndrome of crocodile tears as a result of tuberculoid type of leprosy is reported to lend support that the syndrome may be caused by this disease after a long period of its onset.
Subject(s)
Lacrimal Apparatus Diseases/etiology , Leprosy/complications , Tears , Adult , Facial Paralysis/complications , Humans , Male , SyndromeABSTRACT
A case of the syndrome of crocodile tears as a result of tuberculoid type of leprosy is reported to lend support that the syndrome may be caused by this disease after a long period of its onset.
